Texas Sen. John Cornyn issued a warning that a biotech start‑up, which has secured roughly $30 million to investigate embryonic diseases, is moving ahead with gene‑editing techniques on human embryos. Cornyn, a Republican from Texas, called on the Department of Health and Human Services to confirm that Preventive PBC— a San Francisco‑based company backed by leading tech investors—is complying with all federal rules governing CRISPR‑style gene edits.

Fida Biosystems ApS has added  €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug discov...

RTW Investments is making a licensing deal with a China biotech for an antibody that’s being developed for two related autoimmune conditions called Graves’ disease and thyroid eye disease. As part of the deal, RTW ...

Chai Discovery, a biotech startup with backing from OpenAI, announced a $130 million Series B round at a $1.3 billion valuation on Monday.

🚀 Discover this awesome post from TechCrunch 📖 📂 Category: AI,Biotech & Health,artificial intelligence,Chai Discovery,In Brief,OpenAI,venture capital 📌 Key idea: Chai Discovery, a biotech startup backed by OpenAI, announced a $130 million Series B round at a valuation of $1.3 billion on Monday. The round was led by General Catalyst and Oak HC/FT, the company said. Other participants include: Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite Venture Fund, Lachy Groom, SV Angel, and new investors Glade Brook and Emerson Collective.

Chai Discovery, a biotech startup with backing from OpenAI, announced an $130 million Series B round at a $1.3 billion valuation on Monday. The round was led by General Catalyst and Oak HC/FT, the company said. Other participants include Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, SV Angel, and new investors Glade Brook and Emerson Collective. The firm’s total funding now stands at over $225 million. The company is one in a growing industry that sees AI as a faster route towards drug development. In August, Menlo Ventures…

Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.

Chai Discovery, a biotech startup with backing from OpenAI, announced an $130 million Series B round at a $1.3 billion valuation on Monday. The round was led by General Catalyst and Oak HC/FT, the company said. Other participants include Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, SV Angel, and new investors Glade Brook and Emerson Collective.

Chai Discovery, a biotech startup with backing from OpenAI, announced an $130 million Series B round at a $1.3 billion valuation on Monday. The round was led by General Catalyst and Oak HC/FT, the company said. Other participants include Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, SV Angel, and new investors Glade Brook and Emerson Collective.

A California federal court said it likely lacked jurisdiction over an insurance coverage dispute between a Markel Group Inc. unit and the indicted co-founders of a now-defunct medical testing biotech startup who are living abroad.

– German biotech startup Eversyn is expanding into South Korea, offering advanced cell-free bioproduction technologies for complex HMOs and glycosylated biocompounds, which are crucial for infant nutrition, functional foods, and biopharma applications.– Their proprietary platform enables commercial-scale production of bioactive ingredients that were previously inaccessible, supporting Korean companies in accelerating product pipelines and developing new functional formulations. – Eversyn is actively seeking strategic partnerships in Korea’s nutrition and biopharmaceutical sectors, aiming to deliver high-value oligosaccharides and precision glycosylation solutions through joint development and licensing agreements. German biotechnology company spun off from the Max Planck Institute for Dynamics of Complex Technical

The biotech startup is betting that owners of abandoned oil wells will use the tech to squeeze energy out of their wells.

EpilepsyGTx, a Cambridge-based BioTech startup focused on research and development of  gene therapies to treat refractory epilepsy, today announced it has raised €28 million ($33 million) in Series A financing to advance its lead programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank (who invested €12 million (£10.5 million)), and a global biopharmaceutical company.

EpilepsyGTx, a Cambridge-based BioTech startup focused on research and development of  gene therapies to treat refractory epilepsy, today announced it has raised €28 million ($33 million) in Series A financing to advance its lead programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank (who invested €12 million (£10.5 million)), and a global biopharmaceutical company.

Swedish biotech startup Melt&Marble is transforming the way fats are produced for food and personal care products. By leveraging precision fermentation, the company creates animal-free lipid structures that replicate—or even outperform—conventional fats in taste, texture, and functionality. The company recently closed a €7.3 million Series A funding round led by Industrifonden, with strategic support from Beiersdorf, Valio, Catalyze Capital, Chalmers Ventures…

Harmony Baby Nutrition has secured R$31.8M ($5.8M) from the Brazilian government to create breast-milk-inspired infant formulas through fermentation and set up a new R&D centre. Biotech startup Harmony Baby Nutrition is aiming to bridge the gap between infant formula and...

Firefighters battle more than flames. Beyond smoke, heat, and collapsing structures, they face exposure to harmful chemicals embedded in their protective gear—chemicals that persist long after a blaze is extinguished. Among the most concerning are PFAS, the persistent “forever chemicals” now under global scrutiny. Cambiotics, a Denmark-based biotech startup, is developing a microbiome-driven solution to help reduce this hidden chemical burden.